VIA EDGAR
June 23, 2020
U.S. Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4561
100 F Street, N.E.
Washington, D.C. 20549
Attn: | Christopher Edwards |
Joe McCann
Re: | Fusion Pharmaceuticals Inc. |
Acceleration Request for Registration Statement on Form S-1
File No. 333-238968
Requested Date: | June 25, 2020 | |
Requested Time: | 4:00 p.m. Eastern Standard Time |
Dear Mr. Edwards and Mr. McCann:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Fusion Pharmaceuticals Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 25, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Seo Salimi at (212) 459-7234. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Seo Salimi, by facsimile to (212) 656-1546 or by email at ssalimi@goodwinlaw.com.
[Remainder of page left intentionally blank]
If you have any questions regarding this request, please contact Seo Salimi of Goodwin Procter LLP at (212) 459-7234.
Sincerely, |
FUSION PHARMACEUTICALS INC. |
/s/ John Valliant |
John Valliant |
Chief Executive Officer |
cc: | John Crowley, Chief Financial Officer, Fusion Pharmaceuticals Inc. |
Mitchell Bloom, Esq., Goodwin Procter LLP
Seo Salimi, Esq., Goodwin Procter LLP